Status:
COMPLETED
Positron Emission Tomography(PET) in Lymphoma Assessment
Lead Sponsor:
University Health Network, Toronto
Conditions:
Hodgkin's Lymphoma
Non Hodgkin's Lymphoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study examines the role of a diagnostic test called Positron Emission Tomography (PET) scanning in patients with malignant lymphoma. The primary goal of this study is to find out how well PET sca...
Detailed Description
It is currently unknown whether modifying treatment based on FDG-PET results is appropriate. However, clinicians are increasingly using the FDG-PET result, where obtained, in deciding management. Cons...
Eligibility Criteria
Inclusion
- Group A: Newly Diagnosed
- Patients \> 18 years of age.
- Confirmed diagnosis of HL or NHL (any histology).
- Any Ann Arbor stage.
- Pre-treatment staging including CT of head and neck, chest, abdomen and pelvis, where there is a minimum one equivocal finding on the scan, affecting the assignment of stage or IPI factor (i.e. stage III/IV vs. stage I/II, or a question of extranodal involvement by disease).
- Group B: Response Assessment
- Patients \> 18 years of age.
- Confirmed diagnosis of HL or NHL (any histology).
- Any Ann Arbor stage.
- Pre-treatment staging including CT neck, chest, abdomen and pelvis. If alternate assessment of the neck done by clinical palpitation, ultrasound, or MRI is negative, CT neck is not mandatory.
- Post-treatment staging including CT of head and neck, chest, abdomen and pelvis, at 1 - 6 weeks post-therapy.
- Treated with anthracycline-based chemotherapy, with or without radiation therapy (based on the stage of the disease). For Stage III/IV patients, PET will be done following completion of primary chemotherapy. For stage I/II patients, PET will be done after combined modality therapy, or after chemotherapy alone if this was the primary intention of therapy.
- Patients with residual mass on CT following primary chemotherapy with either "unconfirmed" CR (\>75% decrease in size) or PR (³50% decrease in size), based on International workshop criteria.
Exclusion
- Response Assessment
- None Curative treatment Intent
- After initial therapy the response status is: complete response, stable disease, or progressive disease
Key Trial Info
Start Date :
August 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
103 Patients enrolled
Trial Details
Trial ID
NCT00887718
Start Date
August 1 2007
End Date
June 1 2011
Last Update
December 18 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Health Network, Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9